Showing results (31-40 of 279) with videos related to

Sort By:
Pageof 28
European Journal of Cancer (Oxford, England : 1990)|April 6, 2005
Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?John M Strother, Tomasz M Beer, Robert Dreicer
Journal of the National Cancer Institute|May 5, 2025
Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor-associated AEsEmily L Paton, Jeremy P Cetnar, Janet Freeman-Daily, et al.
Urology|February 19, 2008
Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancerJeremy P Cetnar, S Bruce Malkowicz, Steven C Palmer, et al.
Expert Opinion on Pharmacotherapy|February 18, 2015
Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancerJulie N Graff, Max J Gordon, Tomasz M Beer
Expert Review of Anticancer Therapy|June 25, 2003
Docetaxel (taxotere) in the treatment of prostate cancerTomasz M Beer, Mohammed El-Geneidi, Kristine M Eilers
Anti-Cancer Drugs|September 27, 2006
Dose-escalated abarelix in androgen-independent prostate cancer: a phase I studyTomasz M Beer, Christopher Ryan, Gajanan Bhat, et al.
Anticancer Research|April 19, 2011
Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapyChristine M Barnett, Jason F Flamiatos, Tomasz M Beer
Urology|February 5, 2013
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future researchJulie N Graff, Charles G Drake, Tomasz M Beer
Clinical Genitourinary Cancer|July 25, 2007
Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancerTomasz M Beer, Misty Bergenstock, Karlee Birt, et al.
The Journal of Urology|April 11, 2003
Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapyTomasz M Beer, Mark Garzotto, Kristi M Eilers, et al.
Pageof 28